IRB #

STUDY00020077

Title

[NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to compare any good and bad effects of using the study drugs ramucirumab with pembrolizumab compared to the usual approach alone in participants with previously treated for Non-Small Cell Lung Cancer.

Medical Condition(s)

non-small cell lung cancer

Eligibility Criteria

- Participants must have stage IV or recurrent non-small cell lung cancer
- Participants must not have certain genetic mutations unless they have progressed on usual care therapy
- Participants must have received exactly one line of anti-PD-1 or anti-PDL1 therapy for at least 84 days and must have progressed during or after treatment

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Participants will be on study for up to 3 years from the time of study entry through follow up.

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

SWOG

Recruitment End

06/01/2022

Compensation Provided

No


Go Back